Lybalvi Approved for Schizophrenia, Bipolar I Disorder
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
Mood Disorders
Key Factors ID’d for Bipolar Medication Nonadherence
Patients report side effects, beliefs, and knowledge about bipolar disorder are top reasons for not taking medications
Dexmedetomidine Oral Film Under Review for Agitation With Schizophrenia, Bipolar Disorder
In both trials, BXCL501 demonstrated statistically significant, rapid and durable improvements vs placebo across multiple agitation scales.
Sleep Medications Do Not Improve Sleep Disturbance in Women
Women who initiated sleep medications rated their sleep disturbances similarly after 1 and 2 years.
Lumateperone Under Review for Bipolar Depression
The sNDA submissions are supported by data from 2 global randomized, double-blind, placebo-controlled phase 3 studies.
MPR Weekly Dose Podcast 77
New guidelines on mask use; J&J vaccine update; Novel major depressive disorder treatment gains Priority Review; A scabies topical suspension; And a device to help stroke rehabilitation.
Novel Combination Therapy for Major Depressive Disorder Gets Priority Review
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Psilocybin Compared With Escitalopram for Depression
No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram
Considerable Neurologic, Psychiatric Morbidity Reported After COVID-19
Estimated incidence of neurological or psychiatric diagnosis was 33.62 percent among 236,379 patients
FDA: Risk of Arrhythmias With Lamotrigine in Patients With Heart Disease
Lamotrigine is indicated as monotherapy or adjunctive therapy for epilepsy and for use as maintenance treatment in patients with bipolar I disorder.
